Page last updated: 2024-11-07

estrone and Ovarian Diseases

estrone has been researched along with Ovarian Diseases in 30 studies

Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.

Ovarian Diseases: Pathological processes of the OVARY.

Research Excerpts

ExcerptRelevanceReference
"The aim of the study was to evaluate local E2 and estrone (E1) concentrations in the endometrium and different types of endometriosis lesions, and to correlate them with the expression of estrogen-metabolizing enzymes."3.78Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. ( Desai, R; Handelsman, DJ; Huhtinen, K; Perheentupa, A; Poutanen, M; Salminen, A; Ståhle, M, 2012)
"Endometriosis is a chronic inflammatory disease in which immune response and production of estrogen in endometriotic tissues are involved in the development of the disease."1.39Interleukin-4 and prostaglandin E2 synergistically up-regulate 3β-hydroxysteroid dehydrogenase type 2 in endometrioma stromal cells. ( Akiyama, I; Harada, M; Hasegawa, A; Hirata, T; Hirota, Y; Izumi, G; Koga, K; Kozuma, S; Nagai, M; Osuga, Y; Takamura, M; Urata, Y; Yoshino, O, 2013)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-199026 (86.67)18.7374
1990's2 (6.67)18.2507
2000's0 (0.00)29.6817
2010's2 (6.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Urata, Y1
Osuga, Y1
Akiyama, I1
Nagai, M1
Izumi, G1
Takamura, M1
Hasegawa, A1
Harada, M1
Hirata, T1
Hirota, Y1
Yoshino, O1
Koga, K1
Kozuma, S1
RYDBERG, E1
MATHIESEN, KM1
Huhtinen, K1
Desai, R1
Ståhle, M1
Salminen, A1
Handelsman, DJ1
Perheentupa, A1
Poutanen, M1
ROBERT, H1
Giorgi, EP2
Barlow, JJ1
Logan, CM1
Goldzieher, JW2
Fariss, B1
García, CR1
Cutler, WB1
Rebar, RW1
Erickson, GF1
Yen, SS1
Hochner-Celnikier, D1
Zylber-Haran, E1
Shilo, S1
Palti, Z1
Spitz, IM1
Nagamani, M1
Lingold, JC1
Gomez, LG1
Garza, JR1
Bravo, PW1
Stabenfeldt, GH1
Fowler, ME1
Lasley, BL1
Steingold, KA1
Matt, DW1
DeZiegler, D1
Sealey, JE1
Fratkin, M1
Reznikov, S1
Orlova, VG1
Safarian, GM1
Droesch, K1
Navot, D1
Scott, R1
Kreiner, D1
Liu, HC1
Rosenwaks, Z1
Polson, DW1
Franks, S1
Reed, MJ1
Cheng, RW1
Adams, J1
James, VH1
Turkevich, NM1
Akimova, RN1
Gorevaia, AN1
Ishchenko, MP1
Kartavova, NS1
Mahesh, VG1
McDonough, PG1
Ances, IG1
Haskins, AL1
Ganis, FM1
Miasnikov, LA1
Vinogradova, DA1
Kim, MH2
de Jong, FH1
Baird, DT1
van der Molen, HJ1
Baruk, PH1
Rosenfield, RL1
Fang, VS1
Dupon, C1
Refetoff, S1
Dahinden, UA1
Hauser, GA1
Ryhänen, P1
Järvinen, PA1
Swyer, GI1
Little, V1
Lawrence, DM1
Axelrod, LR1
Weisz, J1
Lloyd, CW1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications[NCT01301885]230 participants (Anticipated)Observational2005-10-31Recruiting
A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating[NCT04278755]Phase 28 participants (Actual)Interventional2020-09-24Terminated (stopped due to Halted prematurely due to COVID-19-related enrollment challenges.)
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320]Phase 223 participants (Actual)Interventional2020-01-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Pre-intervention to Intervention Endpoint in Behavioral Inhibition Subscale Score

The Behavioral Inhibition/Behavioral Activation questionnaire will be used to assess behavioural inhibition (BI). The minimum score on the BI subscale is 7, maximum 28. Greater scores indicate greater BI. Change is defined as the average change in BI from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.43

Change From Pre-intervention to Intervention Endpoint in Binge Eating Sum Score

"Binge eating will be measured using the 8-item binge eating subscale of the Eating Pathology Symptoms Inventory (EPSI), which measures features of binge eating (e.g., consumption of large quantities of food, mindless eating) on a 5-point Likert scale from never to very often. The EPSI scale is designed to assess behavior over the past 28 days. Items are summed for a scale score ranging from 0-32. Higher scores indicate more frequent experiences with binge eating behavior. Change is defined as the average change in the binge eating scale score from pre-intervention to intervention." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC-6.60

Change From Pre-intervention to Intervention Endpoint in Delay Discounting Parameter k

The Monetary Choice Questionnaire will be used to measure delay discounting. Participants will be asked to make a series of hypothetical choices between small, sooner (impulsive) vs. larger, later (self controlled) hypothetical monetary outcomes. k is a hyperbolic function with larger k values indicating more valuation of a larger delayed reward and smaller values indicating preference for more immediate, smaller rewards (more impulsivity). k can range from 0 to .25 with scores of .25 indicating complete valuation of the immediate reward and 0 indicating complete valuation of the larger, delayed reward. Change is defined as the average change in k from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionk value (Mean)
Continuous OC.01

Change From Pre-intervention to Intervention Endpoint in Nucleus Accumbens Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.0423

Change From Pre-intervention to Intervention Endpoint in Prefrontal Cortex Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Prefrontal cortex reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.01

Change From Pre-intervention to Intervention Endpoint in Self-reported Reward Sensitivity Subscale Score

Sensitivity to Punishment/Sensitivity to Reward Questionnaire will be used to measure reward sensitivity. The reward sensitivity subscale will be used, which is rated on a true/false scale with scores ranging 0-24. Higher scores indicate more sensitivity to reward. Change is defined as the average change in reward sensitivity from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.60

Change From Pre-intervention to Intervention Endpoint in Weekly Average Binge-eating Frequency

Binge eating frequency is based on a weekly diary of self-reported binge eating frequency. Participants were asked how many times during the past week they had a binge eating episode. Scores can range from 0 to infinity as frequency is self-reported as the number of binge eating episodes in the previous week. Higher scores indicate more episodes of binge eating. Change is defined as the average change in self-reported binge eating frequency from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionepisodes/week (Mean)
Continuous OC-0.43

Change From Pre-intervention to Intervention Endpoint in Dorsal Striatum Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Dorsal striatum reactivity (defined as caudate signal intensity and putamen signal intensity) to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
CaudatePutamen
Continuous OC-.012.02

Correlation Between Irritability and Reactive Aggression During Hormone Addback

"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)0.18
Hormone Insensitive Women (HS-)0.03

Correlation Between Irritability Subcortical Activation in HS+ During Hormone Addback

"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)0.47

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill -0.8Scale and Threat Attention Bias

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)-0.35
Hormone Insensitive Women (HS-)0.11

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper Scale and Left Amygdala-medial Prefrontal Cortex (PFC) BOLD Connectivity.

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Mean)
Hormone Sensitive Women (HS+)-0.13
Hormone Insensitive Women (HS-)0.49

Correlation Between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper Scale and Right Amygdala-medial Prefrontal Cortex (PFC) BOLD Connectivity.

This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)

Interventioncorrelation coefficient (Number)
Hormone Sensitive Women (HS+)-0.57
Hormone Insensitive Women (HS-)-0.08

Mean BOLD Activation of the Left Amygdala During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)-0.009866667-0.086876444
Hormone Sensitive Women (HS+)0.005316917-0.047401917

Mean BOLD Activation of the Left Caudate During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0077258-0.049988
Hormone Sensitive Women (HS+)-0.0439433330.059099917

Mean BOLD Activation of the Left Nucleus Accumbens During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0691907-0.072512
Hormone Sensitive Women (HS+)-0.0284518180.031632727

Mean BOLD Activation of the Left Putamen During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0383029-0.021029
Hormone Sensitive Women (HS+)-0.0012234620.048155385

Mean BOLD Activation of the Right Amygdala During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.037334-0.15643
Hormone Sensitive Women (HS+)-0.045440.022654

Mean BOLD Activation of the Right Caudate During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.0614070.0058011
Hormone Sensitive Women (HS+)-0.0699190770.045146154

Mean BOLD Activation of the Right Nucleus Accumbens During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.052685333-0.006394444
Hormone Sensitive Women (HS+)0.044384167-0.005181667

Mean BOLD Activation of the Right Putamen During the Affective Posner Task Over Time

"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionArbitrary Units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.002542222-0.080736333
Hormone Sensitive Women (HS+)-0.0075606920.036225385

Mean Left Amygdala-medial Prefrontal Cortex BOLD Connectivity During Implicit Emotion Face Processing Task Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionarbitrary units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.02130.00111
Hormone Sensitive Women (HS+)0.0247-0.0192

Mean Reactive Aggression During Hormone Addback Over Time

"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks

,
InterventionNumber of subtraction responses (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)129.2054.90
Hormone Sensitive Women (HS+)103.0834.62

Mean Right Amygdala-medial Prefrontal Cortex BOLD Connectivity During Implicit Emotion Face Processing Task Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionarbitrary units (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)0.05330.00804
Hormone Sensitive Women (HS+)0.0174-0.0114

Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time

"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks

,
Interventionattention bias in milliseconds (Mean)
Baseline (Visit 3)Hormone Addback (Visit 6)
Hormone Insensitive Women (HS-)36.92-42.35
Hormone Sensitive Women (HS+)-0.57-9.04

Reviews

1 review available for estrone and Ovarian Diseases

ArticleYear
[Insufficiency of the luteal phase].
    Akusherstvo i ginekologiia, 1985, Issue:7

    Topics: Adult; Corpus Luteum; Estrone; Female; Humans; Infertility, Female; Luteal Phase; Ovarian Diseases;

1985

Trials

1 trial available for estrone and Ovarian Diseases

ArticleYear
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 73, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est

1991
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 73, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est

1991
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 73, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est

1991
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 73, Issue:2

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est

1991

Other Studies

28 other studies available for estrone and Ovarian Diseases

ArticleYear
Interleukin-4 and prostaglandin E2 synergistically up-regulate 3β-hydroxysteroid dehydrogenase type 2 in endometrioma stromal cells.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:4

    Topics: Cells, Cultured; Dinoprostone; Drug Synergism; Endometriosis; Estrone; Female; Gene Expression Regul

2013
On the mechanism of the action of oestrogenic hormone preparations in ovarian insufficiency.
    Acta endocrinologica, 1948, Volume: 1, Issue:2

    Topics: Estrogens; Estrone; Female; Gonadal Steroid Hormones; Humans; Ovarian Diseases

1948
Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:11

    Topics: Adult; Endometriosis; Endometrium; Estradiol; Estrone; Female; Humans; Ovarian Diseases; Peritoneal

2012
[Estrogenic insufficiency and pathology of the vagina].
    Gazette medicale de France, 1953, Volume: 60, Issue:11

    Topics: Disease; Estrone; Female; Humans; Ovarian Diseases; Ovary; Vagina

1953
Determination of free and conjugated oestrogens in fluid from human ovaries.
    The Journal of endocrinology, 1967, Volume: 37, Issue:2

    Topics: Adult; Child; Cysts; Estradiol; Estrone; Exudates and Transudates; Female; Glucuronates; Humans; Mid

1967
Estrogen metabolism in the polycystic ovary syndrome. Effect of ovarian wedge resection and clomiphene.
    American journal of obstetrics and gynecology, 1967, Jul-01, Volume: 98, Issue:5

    Topics: Carbon Isotopes; Clomiphene; Cysts; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Ovarian

1967
The polycystic ovary. VII. Intractable uterine bleeding and endometrial hyperplasia possibly related to an extraovarian source of oestrogen.
    Acta endocrinologica, 1967, Volume: 54, Issue:3

    Topics: 17-Ketosteroids; Adrenal Glands; Adult; Androgens; Chromatography; Cysts; Endometrial Hyperplasia; E

1967
Preservation of the ovary: a reevaluation.
    Fertility and sterility, 1984, Volume: 42, Issue:4

    Topics: Adult; Age Factors; Androstenedione; Estrone; Female; Humans; Hysterectomy; Middle Aged; Osteoporosi

1984
Idiopathic premature ovarian failure: clinical and endocrine characteristics.
    Fertility and sterility, 1982, Volume: 37, Issue:1

    Topics: Adult; Amenorrhea; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hor

1982
Increased prolactin response to thyrotropin-releasing hormone in primary ovarian failure.
    Obstetrics and gynecology, 1982, Volume: 59, Issue:3

    Topics: Adult; Amenorrhea; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing

1982
Clinical and hormonal studies in hyperthecosis of the ovaries.
    Fertility and sterility, 1981, Volume: 36, Issue:3

    Topics: Adult; Androstenedione; Diagnosis, Differential; Dihydrotestosterone; Estradiol; Estrone; Female; Go

1981
Ovarian and endocrine patterns associated with reproductive abnormalities in llamas and alpacas.
    Journal of the American Veterinary Medical Association, 1993, Jan-15, Volume: 202, Issue:2

    Topics: Animals; Camelids, New World; Estrogens, Conjugated (USP); Estrone; Female; Luteinizing Hormone; Ova

1993
Transdermal estrogen replacement in ovarian failure for ovum donation.
    Fertility and sterility, 1988, Volume: 50, Issue:6

    Topics: Administration, Cutaneous; Administration, Oral; Embryo Transfer; Estradiol; Estrone; Female; Humans

1988
The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries.
    Clinical endocrinology, 1987, Volume: 26, Issue:5

    Topics: Body Constitution; Estradiol; Estrone; Female; Follicular Phase; Humans; Ovarian Diseases; Polycysti

1987
[Hormonal disorders in patients with fibroadenomatosis of the breast and previous diseases of the ovaries].
    Voprosy onkologii, 1974, Volume: 20, Issue:10

    Topics: 17-Ketosteroids; Adult; Androsterone; Breast Diseases; Castration; Dehydroepiandrosterone; Endocrine

1974
Urinary steroid excretion in a hirsute patient with ovarian cortical stromal hyperplasia and endometrial carcinoma.
    American journal of obstetrics and gynecology, 1969, Jun-15, Volume: 104, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Androgens; Androsterone; Dehydroepiandrosterone; Dexamethasone; Estr

1969
Metabolism of ovarian steroids in a patient with chronic familial anovulation.
    American journal of obstetrics and gynecology, 1970, Dec-01, Volume: 108, Issue:7

    Topics: Adult; Androstanes; Androsterone; Chronic Disease; Dehydroepiandrosterone; Estranes; Estriol; Estron

1970
[Estrogens and androgens in dyshormonal cardiopathy and coronary atherosclerosis in women].
    Kardiologiia, 1971, Volume: 11, Issue:9

    Topics: 17-Ketosteroids; Adult; Androgens; Androsterone; Arteriosclerosis; Chromatography, Thin Layer; Coron

1971
"Gonadotropin-resistant ovaries" syndrome in association with secondary amenorrhea.
    American journal of obstetrics and gynecology, 1974, Sep-15, Volume: 120, Issue:2

    Topics: Adult; Amenorrhea; Androgens; Clomiphene; Depression, Chemical; Dexamethasone; Estradiol; Estrone; F

1974
Ovarian secretion rates of oestrogens, androgens and progesterone in normal women and in women with persistent ovarian follicles.
    Acta endocrinologica, 1974, Volume: 77, Issue:3

    Topics: Adult; Androstenedione; Corpus Luteum; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; M

1974
[Action of certain hormones (sex hormones, ACTH) on the cerebral circulation and mental processes].
    Annales medico-psychologiques, 1973, Volume: 2, Issue:2

    Topics: Adrenocorticotropic Hormone; Aggression; Animals; Brain Edema; Catatonia; Cats; Cerebrovascular Circ

1973
The effects of low doses of depot estradiol and testosterone in teenagers with ovarian failure and Turner's syndrome.
    The Journal of clinical endocrinology and metabolism, 1973, Volume: 37, Issue:4

    Topics: Adolescent; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Half-Life; Humans; Luteinizing

1973
[Experience with estrogen treatment of the climacteric syndrome (author's transl)].
    Therapeutische Umschau. Revue therapeutique, 1974, Volume: 31, Issue:3

    Topics: Climacteric; Estradiol; Estrone; Female; Humans; Middle Aged; Ovarian Diseases; Syndrome

1974
The nature of menstrual disorders in North Finnish women.
    Annales chirurgiae et gynaecologiae Fenniae, 1972, Volume: 61, Issue:2

    Topics: 17-Ketosteroids; Adolescent; Adrenal Gland Diseases; Adult; Amenorrhea; Body Constitution; Diabetes

1972
Further studies on a gonadotrophin stimulation test of ovarian function.
    Proceedings of the Royal Society of Medicine, 1969, Volume: 62, Issue:1

    Topics: Amenorrhea; Estrone; Female; Gonadotropins, Equine; Humans; Ovarian Diseases; Ovary; Polycystic Ovar

1969
The polycystic ovary. V. Alternate pathways of steroid aromatization in normal, pregnancy and polycystic ovaries.
    The Journal of clinical endocrinology and metabolism, 1965, Volume: 25, Issue:9

    Topics: Androgens; Cysts; Estradiol; Estrone; Female; Humans; In Vitro Techniques; Ovarian Diseases; Ovary;

1965
Steroids in cyst fluid from ovaries of normally menstruating women and of women with functional uterine bleeding.
    Journal of reproduction and fertility, 1965, Volume: 10, Issue:3

    Topics: Adult; Androgens; Chemical Phenomena; Chemistry; Cysts; Estradiol; Estrone; Female; Humans; Hydroxyp

1965
Estrogen and androgen production in vitro from 7-3-H-progesterone by normal and polycystic rat ovaries.
    Endocrinology, 1965, Volume: 77, Issue:4

    Topics: Androgens; Animals; Animals, Newborn; Chromatography, Paper; Chromatography, Thin Layer; Cysts; Estr

1965